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Tumors develop through multiple stages, implicating multiple effectors, but the tools to assess how candidate genes
contribute to stepwise tumor progression have been limited. We have developed a novel system in which progression
of phenotypes in a mouse model of pancreatic islet cell tumorigenesis can be used to measure the effects of genes
introduced by cell-type-specific infection with retroviral vectors. In this system, bitransgenic mice, in which the rat
insulin promoter (RIP) drives expression of both the SV40 T antigen (RIP-Tag) and the receptor for subgroup A avian
leukosis virus (RIP-tva), are infected with avian viral vectors carrying cDNAs encoding candidate progression factors.
Like RIP-Tag mice, RIP-Tag; RIP-tva bitransgenic mice develop isolated carcinomas by ;14 wk of age, after progression
through well-defined stages that are similar to aspects of human tumor progression, including hyperplasia,
angiogenesis, adenoma, and invasive carcinoma. When avian retroviral vectors carrying a green fluorescent protein
marker were introduced into RIP-Tag; RIP-tva mice by intra-cardiac injection at the hyperplastic or early dysplastic
stage of tumorigenesis, approximately 20% of the TVA-positive cells were infected and expressed green fluorescent
proteins as measured by flow cytometry. Similar infection with vectors carrying cDNA encoding either of two
progression factors, a dominant-negative version of cadherin 1 (dnE-cad) or Bcl-xL, accelerated the formation of islet
tumors with invasive properties and pancreatic lymph node metastasis. To begin studying the mechanism by which
Bcl-xL, an anti-apoptotic protein, promotes invasion and metastasis, RIP-Tag; RIP-tva pancreatic islet tumor cells were
infected in vitro with RCASBP-Bcl-xL. Although no changes were observed in rates of proliferation or apoptosis, Bcl-xL
altered cell morphology, remodeled the actin cytoskeleton, and down-regulated cadherin 1; it also induced cell
migration and invasion, as evaluated using two-chamber transwell assays. In addition, myosin Va was identified as a
novel Bcl-xL-interacting protein that might mediate the effects of Bcl-xL on tumor cell migration and invasion.
Citation: Du YN, Lewis BC, Hanahan D, Varmus H (2007) Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell
invasion. PLoS Biol 5(10): e276. doi:10.1371/journal.pbio.0050276
Introduction
Cancer typically arises by a multi-step process during which
cells acquire activating mutations in oncogenes and inactivating
mutations in tumor suppressor genes [1]. By comparing cancer
tissues with their normal counterparts, it is possible to identify
many differences in cellular, molecular, and biological proper-
ties. For example, transcriptional proﬁling and genome
sequencing methods have documented alterations in gene
expression and somatic mutations in cancers [2,3]. Several types
of cancers share common somatic changes or display changes in
the same functional pathways, revealing the underlying
principles that drive the transformation of normal cells into
highly malignant derivatives [4].
Mouse models of human cancers provide important
experimental systems for understanding the complexities of
human cancer pathogenesis [5,6]. However, in most mouse
models, mutant genes have been more clearly implicated in
the initiation than in the progression of cancer, even when
newer methods, such as Cre/loxP-mediated recombination or
tetracycline- or estrogen-based gene regulation, are used to
produce a particular gene product conditionally in a tissue-
speciﬁc and time-controlled manner [7,8]. Moreover, it is
time-consuming and expensive to generate alterations in the
mouse germ line for each gene of interest.
Seeking to improve means for studying later stages in
tumorigenesis, we have developed a strategy for assessing
causal links between individual genes and speciﬁc cellular
changes during tumor progression. The strategy is based on
the use of a transgene that encodes the receptor for subgroup
A avian leukosis virus, TVA, allowing cell-speciﬁc infection
with avian retroviral vectors during tumor development
[9,10]. The RIP1-Tag2 (or RIP-Tag) transgenic mouse [11] was
chosen as a platform to study the effects of candidate genes in
tumor progression. In this well-characterized model, SV40 T
antigen is expressed under the control of the Rat insulin
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PLoS BIOLOGYpromoter (RIP) in the b cells of pancreatic islets, providing
the driving force for tumor initiation by blocking the
activities of the Rb and p53 tumor suppressors. The trans-
genic mice develop multifocal pancreatic b-cell tumors
through well-deﬁned stages that resemble lesions of human
tumor development and progression. The natural focal
distribution of the target tissue, into ;400 focal nodules,
has facilitated identiﬁcation and quantiﬁcation of the
distinguishable stages in islet tumorigenesis, which include
hyperplasia or low-grade dysplasias (‘‘hyperplastic islets’’),
high-grade angiogenic dysplasias (‘‘angiogenic islets’’), encap-
sulated, noninvasive islet tumors (IT, adenomas), and distinc-
tive grades of invasive carcinoma [12].
Using a RIP-tva transgene to express the TVA receptor in b
cells of the pancreas, we demonstrate that candidate genes
can be introduced somatically into developing neoplastic b-
cell lesions in RIP-Tag; RIP-tva bitransgenic mice by infection
with a subgroup A avian retroviral vector, termed RCASBP
(subgroup A replication-competent avian leukosis virus with
a splice acceptor and the Bryan-RSV pol gene) [13,14], thereby
modulating tumorigenesis. By doing so, we have established
the functional roles of two candidate progression factors, a
dominant-negative form of cadherin 1 (dnE-cad) and Bcl-xL,
when introduced stochastically in incipient neoplasias. Our
study also reveals an unexpected activity of Bcl-xL in altering
the actin cytoskeleton and promoting invasiveness, ﬁndings
substantiated by analysis of cultured tumor cells. Our results
suggest that targeted somatic delivery of candidate progres-
sion factors via retrovirus vectors will be useful for identify-
ing factors and dissecting mechanisms that underlie advanced
stages of tumorigenesis.
Results
Generation and Characterization of RIP-tva Transgenic
Mice
The general strategy employed in this work involves
equipping pancreatic b cells with TVA, the cell surface
receptor for subgroup A avian leukosis viruses [9,10], so that
the cells are susceptible to the RCASBP vector [15] derived
from those viruses. To that end, we generated transgenic mice
that express TVA under the control of the RIP exclusively in
the b cells of pancreatic islets (Figure 1A–1C). Three
independent lines of RIP-tva mice transmitted the transgene
in a simple Mendelian pattern of inheritance.
To detect TVA on the surface of pancreatic cells in RIP-tva
newborn and adult mice, we performed immunoﬂuorescent
staining with a rabbit polyclonal anti-TVA antibody on
pancreatic sections. To identify pancreatic islets, we co-
stained the sections with goat antisera against PDX1, a
transcription factor expressed in pancreatic precursor cells
and islet b cells. In both newborn and adult animals, TVA was
observed in cells within the islets in all three RIP-tva
Figure 1. Characterization of RIP-tva Transgenic Mice
(A) The RIP-tva transgene. The 800-bp tva cDNA was cloned into a XbaI/
HindIII-digested plasmid that contains the 59 flanking region of the rat
insulin II gene and transcription termination sequences (An) (details in
Materials and Methods).
(B and C) Confocal microscopic images show immunofluorescent
membrane staining of TVA (red) and nuclear staining of PDX1 (green)
in pancreatic sections of 2-d-old RIP-tva transgenic (B) and non-
transgenic (C) animals. Nuclei were stained with DAPI (blue). Original
magnification, 6303. The images are representative of 20 fields from 12
mice analyzed.
(D) Confocal microscopic immunofluorescent image of hyperplastic islet
cells revealed TVA (red) and PDX1 (green) in pancreatic section of a 7-wk-
old RIP-Tag; RIP-tva bitransgenic animal. The image is representative of
15 fields from three mice analyzed.
(E) The adjacent section of (D) was immunostained for SV40 T antigen.
The image is representative of 15 fields from three mice analyzed.
Ex, exocrine tissue.
doi:10.1371/journal.pbio.0050276.g001
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Author Summary
Cancer cells accumulate multiple genetic alterations. Some of these
contribute to tumor development while others are a mere by-
product of genomic instability. To determine whether a candidate
gene can promote tumor development, we have developed a novel
experimental system using engineered viruses to deliver genes into
premalignant lesions. We used genetically engineered mice in which
both an oncogene (SV40 T antigen) and a specific docking molecule
for the virus are produced in b cells in the pancreatic islets of
Langerhans. Tumors form in only a subset of the islets expressing
this oncogene, indicating that tumor development requires other
events. Since these precancerous cells also express the virus docking
molecule, we could deliver candidate progression genes via the
virus to see whether they contributed to tumor progression. We
show that genes encoding two proteins (a survival factor, Bcl-xL, and
an inhibitory form of the cell adhesion molecule cadherin 1) can be
delivered into premalignant b cells and thereby enhance tumori-
genesis. Both of these proteins were previously implicated in tumor
progression, confirming that our technique can identify such
progression genes. Moreover, we find that Bcl-xL promotes tumor
cell migration and invasion by a mechanism distinct from its known
role in cell survival.transgenic lines with similar expression levels (Figure 1B and
data not shown). No TVA staining was detected in either
exocrine cells from the RIP-tva mice (Figure 1B) or
pancreases from non-transgenic animals (Figure 1C). In
addition, expression of TVA in other organs was not detected
by immunoﬂuorescent staining (data not shown). We
conclude that TVA is produced speciﬁcally in the pancreatic
b islets of RIP-tva transgenic mice, although we cannot rule
out the possibility that other cell types may express the
transgene at levels below those detectable with the method
employed.
Examination of pancreatic tissues from newborn and adult
animals did not reveal any signiﬁcant differences in islet
morphology between RIP-tva animals and non-transgenic
littermates (data not shown). The distribution and presence
of cells expressing insulin II (known as insulin), glucagon,
somatostatin, and pancreatic polypeptide were also similar in
RIP-tva mice and non-transgenic littermates (data not shown),
indicating that the viral receptor, TVA, itself did not perturb
any of the properties of islet cells that might be relevant to
this study.
Gene Transfer to RIP-Tag; RIP-tva Cells In Vitro and In Vivo
To prepare to study the effects of candidate progression
factors, introduced by virus infection, on the course of tumor
development, one of the three RIP-tva lines was crossed with
the RIP-Tag line to generate bitransgenic RIP-Tag; RIP-tva
mice (Figure 2A). It has been shown that the strain back-
grounds inﬂuence the tumorigenesis of RIP-Tag mice, and the
course of tumorigenesis is more consistent in a C57BL/6
background [16,17]. We therefore backcrossed RIP-tva mice
from a mixed genetic background for ten generations onto a
pure C57BL/6 background with RIP-Tag.
We initially veriﬁed the co-production of TVA and SV40 T
antigen in the islets of 7-wk-old bitransgenic mice (Figure 1D
and 1E). We then determined whether the RIP-tva transgene
conferred susceptibility to infection by RCASBP viruses in
islet cells derived from the bitransgenic mice. Cell prolifer-
ation is required for successful infection by RCASBP
retroviruses, but adult islet cells have low proliferation rates
[18]. To increase the fraction of proliferating cells, cultures
were established from b-cell tumors from RIP-Tag; RIP-tva
bitransgenic mice, and the tumor cells were infected with a
RCASBP vector carrying the green ﬂuorescent protein (GFP)
marker (RCASBP-GFP). Analysis by ﬂuorescence microscopy
at 1 wk after the second of two rounds of infection revealed
that more than 70% of the tumor cells expressed GFP,
demonstrating that cells derived from the b-cell tumors were
readily infectable by RCASBP in vitro (Figure 2B and 2C). No
green ﬂuorescence was detectable in uninfected cells (data
not shown).
We next evaluated gene transfer in vivo. We chose to infect
RIP-Tag; RIP-tva bitransgenic animals at 7 wk after birth, an
age when hyperplastic islets develop in RIP-Tag mice. A
concentrated preparation of RCASBP-GFP viruses (0.1 ml;
.10
8 infectious units per milliliter) was delivered by intra-
cardiac injection to ensure distribution of viruses to all
organs fed by the arterial circulation. Two weeks after
infection, the percentage of GFP-expressing TVA-positive
cells in the islets was determined by ﬂuorescence-activated
cell sorting (FACS) (Figure 2D). Suspensions of single
pancreatic cells were prepared as described in Materials
and Methods, using a protocol modiﬁed from Shih et al. [19]
and Dor et al. [20]. Approximately 11%–18% of the cells in
these preparations were TVA-positive when isolated from
bitransgenic animals, and about 20% of the TVA-positive
cells expressed GFP (Figure 2D, lower right panel), implying
that the infection efﬁciency in vivo is around 20% in TVA-
positive cells. The green ﬂuorescence was not due to
autoﬂuorescence, because almost no ﬂuorescence was ob-
served in pancreatic cells from wild-type or RIP-tva mono-
transgenic animals injected with RCASBP-GFP or from
bitransgenic mice injected with RCASBP viruses encoding
human placental alkaline phosphatase (RCASBP-ALPP; pre-
viously known as RCASBP-AP) (Figure 2D). The lack of
detectable infection in adult RIP-tva monotransgenic animals
injected with RCASBP-GFP conﬁrmed that proliferation of
the TVA-expressing cells is necessary for successful infection.
dnE-cad Promotes Invasive Tumors and Metastasis in RIP-
Tag; RIP-tva Mice
To ascertain whether the development of b-cell tumours
could be accelerated by the somatic delivery of factors
previously reported to promote tumor progression in RIP-
Tag mice, we infected RIP-Tag; RIP-tva bitransgenic mice with
RCASBP vectors that carry cDNA encoding dnE-cad, a
mutant protein lacking the extracellular, adhesion-mediating
domain of cadherin 1 [21]. In previous studies involving RIP1-
Tag2; RIP1-dnE-cad bitransgenic mice, suppression of cadher-
in 1 function by expression of a dnE-cad cDNA enhanced and
accelerated the progression from noninvasive ITs (adenomas)
to invasive carcinomas and increased the frequency of
otherwise rare lymph node metastasis [22].
We injected high titer stocks (.10
8 infectious units per
milliliter) of RCASBP viruses carrying cDNA encoding dnE-
cad into 7-wk-old RIP-Tag; RIP-tva bitransgenic animals by
the intra-cardiac route (Figure 3A). Nine weeks later,
pancreases from 16-wk-old mice were harvested for histo-
logical staging and grading of the lesions according to
established criteria [23]. In brief, tumors were scored as IT
(noninvasive tumor; .1 mm in diameter; Figure 3B); invasive
carcinoma type 1 (IC-1; .1 mm in diameter; focal regions of
invasion; Figure 3C); or invasive carcinoma type 2 (IC-2;
variable sizes; widespread invasion; Figure 3D). Pancreatic
sections were also subjected to immunohistochemical tests
for the expression of synaptophysin, a neuroendocrine
marker found in all types of islet cells, and for insulin II, a
b-cell marker.
By counting and classifying pancreatic lesions (Table 1), we
found that (i) the average tumor incidence in bitransgenic
mice infected with RCASBP-dnE-cad (n ¼ 11) was 1.5-fold
higher than that in bitransgenic mice injected with the
control RCASBP-ALPP viruses (n ¼ 6); (ii) mice injected with
RCASBP-dnE-cad (n ¼ 11) exhibited a higher incidence of
invasive carcinomas than mice injected with the control
viruses (n ¼ 6); and (iii) mice injected with RCASBP-dnE-cad
had a higher tumor burden than controls (p¼0.003, n¼6 for
each group, Wilcoxon rank sum test). By staining pancreatic
lymph nodes with antisera against insulin II and synaptophy-
sin to search for metastatic b-cell tumors, we found that six of
the 15 mice infected with RCASBP-dnE-cad developed
metastases to the pancreatic lymph nodes (Table 1; Figure
4A, upper panel); metastases were not detected in mono-
transgenic RIP-Tag mice of the same age or in RIP-Tag; RIP-
PLoS Biology | www.plosbiology.org October 2007 | Volume 5 | Issue 10 | e276 2257
Mouse Model for Assessing Tumor Progressiontva bitransgenic mice infected with RCASBP-ALPP.N o
metastases to other distant organs (liver, kidney, lung, heart,
or thymus) were observed in the animals infected with
RCASBP-dnE-cad or RCASBP-ALPP, consistent with the
ﬁndings in RIP1-Tag2; RIP1-dnE-cad bitransgenic mice. Taken
together, these data indicate that the RIP-Tag; RIP-tva mice
can be used to assess the effects of genes of interest on tumor
progression in vivo, with targeted somatic delivery of dnE-cad,
largely recapitulating the effects seen with a traditional
transgenic approach that constitutively expresses the candi-
date progression factor in all of the target cells throughout
ontogeny [22].
Figure 2. Infection of RIP-Tag; RIP-tva Pancreatic Islet Cells In Vitro and In Vivo
(A) Experimental strategy. RIP-Tag transgenic mice were crossed with RIP-tva transgenic mice to generate RIP-Tag; RIP-tva bitransgenic mice. For in vitro
experiments, tumors from 16-wk-old bitransgenic mice were isolated and cultured in vitro, and tumor cells were infected with RCASBP viruses (left). For
in vivo infection, RCASBP viruses were delivered into 7-wk-old bitransgenic animals through intra-cardiac (I.C.) injection. Characterization of islet cells/
tumors was performed 2, 5, or 9 wk after viral delivery (right).
(B and C) Example of infection in vitro with an RCASBP vector. Bright-field image of RIP-Tag; RIP-tva tumor cells infected with RCASBP-GFP in vitro (B)
and fluorescent image showing GFP expression (C) were taken 1 wk after infection. The images are representative of more than 20 fields from two
independent infections.
(D) Flow cytometry plots of islet cells from wide-type mouse (C57BL/6) injected with RCASBP-GFP (upper left), RIP-tva transgenic mouse injected with
RCASBP-GFP (upper right), and RIP-Tag; RIP-tva bitransgenic mice injected with RCASBP-ALPP (lower left) or RCASBP-GFP (lower right) via intra-cardiac
injection. RCASBP viral supernatants were delivered at the age of 7 wk. Two weeks later, mice were sacrificed, and pancreases were digested into single-
cell suspension. Cells were analyzed for TVA
þ and GFP by FACS. The percentage of cells in each gated panel is indicated in the corners. Approximately
11%–18% of pancreatic cells isolated from RIP-tva or RIP-Tag; RIP-tva bitransgenic mice by this method were TVA
þ(upper quadrants), and about 20% of
TVA
þ cells from bitransgenic animals infected with RCASBP-GFP expressed GFP.
doi:10.1371/journal.pbio.0050276.g002
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Mouse Model for Assessing Tumor ProgressionBcl-xL Increases Tumor Invasion and Metastasis in RIP-Tag;
RIP-tva Mice
We next investigated a second progression factor, Bcl-xL, a
member of the anti-apoptotic subgroup of the BCL2 family of
apoptotic regulators [24] via somatic gene transfer. In
previous studies, constitutive expression of Bcl-xL via a
RIP7-Bcl-xL transgene was found to suppress apoptosis and
alternatively accelerate or enable islet tumorigenesis in
mouse models of cancer evoked by SV40 T antigen [25] or
MYC [26], respectively. We sought to assess the effects of
expressing exogenous Bcl-xL in sporadic cells, beginning after
neoplastic development had ensued, as contrasted to its
constitutive expression throughout tumorigenesis in the
bitransgenic RIP1-Tag2; RIP7-Bcl-xL mice.
We injected high titer stocks of RCASBP viruses carrying
cDNA encoding Bcl-xL into 7-wk-old RIP-Tag; RIP-tva
bitransgenic mice, and subsequently harvested pancreases at
16 wk of age for histopathology (Table 1). We observed that (i)
the average tumor incidence in bitransgenic mice infected
with RCASBP-Bcl-xL (n ¼ 10) was 2-fold higher than that in
bitransgenic mice injected with the control RCASBP-ALPP
viruses (n ¼ 6); (ii) mice infected with RCASBP-Bcl-xL (n ¼ 10)
exhibited a higher incidence of invasive carcinomas than did
mice that received the control viruses (n ¼ 6); and (iii) mice
infected with RCASBP-Bcl-xL displayed a higher tumor
burden than controls (p ¼ 0.003, n ¼ 6 for each group,
Wilcoxon rank sum test). We also found that seven of the 15
mice infected with RCASBP-Bcl-xL developed metastases to
the pancreatic lymph nodes, but no metastases to other
organs (Table 1; Figure 4A, lower panel). Therefore, over-
expression of Bcl-xL, beginning in hyperplastic or early
dysplastic lesions, after tumorigenesis had been initiated,
increased tumor burden, incidence, and invasion, and
facilitated lymph node metastasis (p ¼ 0.05, Fisher’s exact
test).
Histological analysis of the tumors revealed that insulin II
Figure 3. RIP-Tag; RIP-tva Islet Tumorigenesis and Examples of Histological Categories
(A) Schematic representation of the RIP-Tag; RIP-tva islet tumorigenesis (modified from the RIP1-Tag2 Manual, Hanahan laboratory, unpublished).
RCASBP retroviruses carrying genes of interest were introduced into the hyperplastic islets of 7-wk-old mice through intra-cardiac injection. Mice were
sacrificed at 16 wk of age for histological staging and grading to determine tumor incidence and phenotype as shown in Table 1.
(B–D) Hematoxylin and eosin stain of representative examples of IT (B), IC-1 (C), and IC-2 (D).
doi:10.1371/journal.pbio.0050276.g003
Table 1. Impact of RCAS-Bcl-xL and RCAS-dnE-cad on Tumorigenesis In Vivo
cDNA Carried
by RCASBP
Tumor Incidence
(per Mouse)
Tumor Burden
(per Mouse)
Tumor Phenotype Pancreatic Lymph
Node Metastasis Adenoma Invasive Carcinoma
ALPP 7.0 6 1.7 99.7 6 19.4 26% 74% 0/10 mice
dnE-cad 10.3 6 3.3 176.5 6 57.5 4% 96% 6/15 mice
Bcl-xL 13.7 6 5.5 151.4 6 25.0 6% 94% 7/15 mice
RCASBP retroviruses carrying ALPP, dnE-cad, or Bcl-xL were introduced to RIP-Tag; RIP-tva mice as illustrated in Figure 3A. Mice were sacrificed at 16 wk of age for measurement of tumor
burden, histological staging, and grading (see Figure 3B–3D).
doi:10.1371/journal.pbio.0050276.t001
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Mouse Model for Assessing Tumor Progressionexpression was not detectable in a small subset (;4.5%) of IC-
2i nRIP-Tag; RIP-tva mice infected with RCASBP-Bcl-xL or
RCASBP-dnE-cad (Figure 4B, right panels). All tumors stained
with antisera recognizing the neuroendocrine marker syn-
aptophysin (Figure 4B, left panels), suggesting a process of de-
differentiation or transformation of less mature cells into an
‘‘anaplastic’’ islet carcinoma, a phenotype not observed in
bitransgenic animals that were uninfected or infected with
control vectors.
Bcl-xL is known to protect cells from apoptosis [24]. We
therefore investigated whether the increased invasive and
metastatic behavior of the tumors from mice infected with
RCASBP-Bcl-xL was due to increased cell survival, producing
greater cell numbers and a higher probability of tumor
spread, or due to some other properties of Bcl-xL. We
observed no signiﬁcant differences in proliferative or
apoptotic indices by staining tumors from 16-wk-old mice
previously infected with RCASBP-ALPP, RCASBP-Bcl-xL, or
RCASBP-dnE-cad with antisera against a proliferation marker,
MKI67 (antigen identiﬁed by monoclonal antibody Ki67), or
against activated caspase 3 (Kruskal-Wallis nonparametric
test, three-way test, p ¼ 0.79 and 0.69, respectively) (Figure
5A). These results suggest that the increased invasive and
metastatic properties were not due to the effects of Bcl-xL on
proliferation or survival of the cancer cells at the stages of
adenomas and carcinomas. However, it remains possible that
Bcl-xL provides some protection from apoptosis at the
metastatic stage or earlier stages in tumorigenesis, as cell
death is greatly reduced in both hyperplastic and angiogenic
islets in RIP1-Tag2; RIP7-Bcl-xL bitransgenic mice that
constitutively express high levels of Bcl-xL in all b cells in
normal islets and at all stages of tumorigenesis [25]. Since
only a small fraction of the b cells in premalignant lesions
became somatically infected in our experiments, such effects
would likely be masked by the preponderance of uninfected
cells in those lesions.
To determine whether the effects of Bcl-xL occurred early
or late in the neoplastic process, we examined sections of
pancreases from RIP-Tag; RIP-tva mice at 2 and 5 wk after
RCASBP-Bcl-xL delivery (9 and 12 wk of age, respectively), as
well as 9 wk after infection (Figure 5B and 5C). This
experiment not only conﬁrmed the ﬁndings presented in
Table 1 at late times after infection, but also showed that the
effects of Bcl-xL could be observed as early as 2 wk after viral
delivery. RIP-Tag; RIP-tva mice infected with RCASBP-Bcl-xL
exhibited higher tumor burdens (for three ages p   0.009,
Wilcoxon rank sum test) and a greater tumor incidence at all
three ages (9, 12, and 16 wk of age) than did the bitransgenic
control mice infected with RCASBP-ALPP (Figure 5B). In
addition, at all ages the numbers of IC-1 and IC-2 were higher
in mice infected with RCASBP-Bcl-xL than in mice that
received RCASBP-ALPP; furthermore, the small invasive
carcinomas appeared before ITs in RIP-Tag; RIP-tva mice at
2 wk after RCASBP-Bcl-xL delivery (Figure 5C). These ﬁndings
suggest that some of the hyperplastic or angiogenic islets
develop highly invasive carcinomas (variable sizes) without
progressing through a noninvasive IT stage (.1m mi n
diameter), a phenotype ﬁrst observed in bitransgenic mice
that express both SV40 T antigen and a receptor tyrosine
kinase, the insulin-like growth factor (IGF) 1 receptor
(IGF1R), in the pancreatic islets [23]. No signiﬁcant effects
of Bcl-xL on proliferative or apoptotic indices in the tumors
were observed at 2 and 5 wk after viral delivery (data not
shown). Thus, introducing RCASBP-Bcl-xL into RIP-Tag; RIP-
tva mice with islet cell hyperplasia has a substantial impact on
tumor burden, tumor incidence, and invasive potential
within 2 wk after infection.
Confirmation of the Presence of RCASBP-Bcl-xL Proviral
DNA in Tumors and Metastases from Mice Infected with
RCASBP-Bcl-xL
Since infection of bitransgenic mice with RCASBP-Bcl-xL
increases the number of tumors by about 2-fold at 16 wk of
age (Table 1; Figure 5), we anticipated that about half of the
Figure 4. Detection of Metastasis and Assessment of the Differentiation Status of IC-2 from Mice Infected with RCASBP-Bcl-xL and RCASBP-dnE-cad
(A) Representative images of lymph node metastases found in six mice infected with RCASBP-dnE-cad (upper panel) or in seven mice infected with
RCASBP-Bcl-xL (lower panel). Immunohistochemical staining of insulin II in metastatic b-cell tumor cells in pancreatic lymph nodes is shown. Original
magnification, 2003.
(B) About 4.5% of IC-2 found in mice infected with RCASBP-dnE-cad or RCASBP-Bcl-xL do not express insulin II. Immunohistochemical staining of
synaptophysin, a neuroendocrine marker (left), and insulin II (right) in b-cell tumor cells in pancreatic sections from mice injected with RCASBP-dnE-cad
(upper panel) or RCASBP-Bcl-xL (lower panel). Original magnification, 2003 (upper panel) and 1003 (lower panel).
doi:10.1371/journal.pbio.0050276.g004
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Mouse Model for Assessing Tumor Progressiontumors would contain avian proviral DNA as evidence of
infection that confers a selective growth advantage. To test
this prediction, we isolated genomic DNA from freshly
microdissected tumors or from tumors in parafﬁn-embedded
sections, and we then performed PCR using primers speciﬁc
to RCASBP sequences. Using materials from the experiment
shown in Figure 5, we detected RCASBP DNA in eight of 11
tumors (72%), six of 12 tumors (50%), and ten of 25 tumors
(40%) harvested 2, 5, and 9 wk after viral delivery, respectively
(Figure 6A and data not shown). In contrast, RCASBP DNA
was detectable in only two of 20 tumors from mice sacriﬁced
9 wk after infection with the control RCASBP-ALPP viruses
(Figure 6B), which is consistent with an in vivo infection
efﬁciency of at least 10%. These results support the
hypothesis that infection leading to production of Bcl-xL,
but not the control infection with RCASBP-ALPP, provides a
selective growth advantage to islet cells during tumorigenesis
in RIP-Tag; RIP-tva mice.
Because only small amounts of DNA were obtained from
these small tumors, we were unable to assess the clonality of
tumors containing RCASBP-Bcl-xL by restriction mapping
and thereby determine if they arose from the expansion of
single infected cells. In addition, no suitable anti-Bcl-xL
antibodies were found to identify tumors expressing Bcl-xL
by immunohistochemistry. We observed lymph node meta-
stases only in mice infected with RCASBP-Bcl-xL or RCASBP-
dnE-cad, not in mice infected with RCASBP-ALPP, so we
considered the possibility that metastases had arose from
tumor cells expressing Bcl-xL or dnE-cad. We conﬁrmed the
presence of RCASBP proviral DNA in all nine lymph node
metastases from mice infected with RCASBP-Bcl-xL or
RCASBP-dnE-cad (Figure 6C). We cannot, however, claim that
all the metastatic cells were derived from RCASBPP-Bcl-xL- or
RCASBP-dnE-cad-infected cells.
Bcl-xL Induces Changes in Cell Morphology, Migration,
and Invasion In Vitro
Since tumor invasion and metastasis often involve modu-
lation of the actin cytoskeleton to increase cell motility
[27,28], we evaluated the actin cytoskeleton in tumors from
RIP-Tag; RIP-tva mice infected with RCASBP-Bcl-xL, using an
immunoﬂuorescence assay with rhodamine-phalloidin to
display ﬁlamentous actin (F-actin). We observed a dramatic
rearrangement of the actin cytoskeleton in invasive carcino-
Figure 5. RCASBP-Bcl-xL Enhances Tumorigenesis in RIP-Tag; RIP-tva Mice
RIP-Tag; RIP-tva mice were injected with RCASBP-ALPP (control), RCASBP-Bcl-xL, or RCASBP-dnE-cad at 7 wk of age, and were sacrificed at the indicated
ages for histopathological analysis.
(A) Proliferative index (upper panel) and apoptotic index (lower panel) in the tumors from 16-wk-old mice injected with RCASBP-ALPP (control), RCASBP-
Bcl-xL, or RCASBP-dnE-cad were determined. Pancreatic sections were stained with antibodies against Ki67 or activated caspase 3. Data shown are the
mean percentage 6 standard deviation from ten tumors of each group.
(B and C) Mice injected with RCASBP-ALPP (control) or RCASBP-Bcl-xL were sacrificed at the indicated ages to evaluate tumor burden (B, upper panel). A
standard formula for tumor volume was applied (volume [mm
3]¼0.523width
23length). Tumor burden per mouse is the sum of the tumor volume.
Pancreatic sections were stained with synaptophysin for identification of islet cells. Tumor incidence was determined (B, lower panel), and the different
categories of tumors were counted (C).
doi:10.1371/journal.pbio.0050276.g005
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in tumors from age-matched animals infected with RCASBP-
ALPP (Figure 7A), suggesting that Bcl-xL remodels the actin
cytoskeleton to increase cell motility.
To further understand the effects of Bcl-xL on tumor cells,
we infected a b-cell tumor cell line (bTC-N134) derived from
an uninfected RIP-Tag; RIP-tva mouse with RCASBP-Bcl-xL.I n
addition, we infected the tumor cells with RCASBP-dnE-cad or
RCASBP-GFP, to control for any effects of retroviral
infection. Two weeks after infection with RCASBP-Bcl-xL,
the tumor cells became more elongated compared to the
uninfected parental cells and to the cells infected with either
RCASBP-GFP or RCASBP-dnE-cad (Figure 7B). Staining with
rhodamine-phalloidin demonstrated decreased cortical actin
and a less organized epithelial sheet in tumor cells infected
with RCASBP-Bcl-xL, but not in the other cultures (Figure 7C).
Taken together, these results suggest that Bcl-xL promotes
remodeling of the actin cytoskeleton, affecting cell shape and
adhesion.
To examine whether Bcl-xL increased the ability of
morphologically altered cells to migrate or invade, we
performed two-chamber migration and invasion assays. In
the migration assay, uninfected tumor cells (bTC-N134) or
tumor cells infected with RCASBP-GFP, RCASBP-Bcl-xL, or
RCASBP-dnE-cad were seeded in the upper chambers of
transwell inserts with 8-lm porous polycarbonate mem-
branes. We then measured cell migration along a serum
gradient through the membrane to the bottom of the
chambers. After a 72-h incubation, the number of migratory
tumor cells infected with RCASBP-Bcl-xL or RCASBP-dnE-cad
was approximately 1,000-fold higher than that of uninfected
cells or cells infected with RCASBP-GFP (Figure 8A). In the
invasion assay, 8-lm porous polycarbonate membranes were
replaced with polyester membranes coated with basement
membrane matrix, Matrigel. The tumor cells infected with
RCASBP-Bcl-xL invaded through Matrigel about 20-fold more
efﬁciently than those infected with RCASBP-dnE-cad, and
none of the uninfected parental cells or the cells infected
with RCASBP-GFP had the ability to invade (Figure 8B). The
results reveal that Bcl-xL has profound effects on cell
migration and invasion in vitro.
To ensure that any increase in cell migration and invasion
in vitro was not simply due to an increase of cell number by
the anti-apoptotic effect of Bcl-xL, immunocytochemistry
using antibodies for Ki67 and activated caspase 3 was
performed to assay cell proliferation and cell survival. The
frequency of Ki67-positive cells and activated-caspase-3-
positive cells remained similar in all three of the infected
tumor cell lines compared to the uninfected parental cell line
(Figure 8C and 8D). These results, consistent with our in vivo
data (Figure 5A), suggest that Bcl-xL is able to promote cell
migration and invasion without changing cell proliferation or
survival.
Reduction of Endogenous Cadherin 1 in Tumor Cells
Infected with RCASBP-Bcl-xL
In addition to the cytoskeleton rearrangement, loss of
cadherin 1 can also confer invasive properties on tumor cells
[22]. To examine if the expression of cadherin 1 was altered in
the tumor cells infected with RCASBP-Bcl-xL, we measured
cadherin 1 levels by Western blot analysis using an anti–
cadherin 1 antibody (clone 36) (Figure 8E). Cadherin 1
Figure 6. PCR Analysis to Verify the Presence of the RCASBP Proviral DNA in the Tumors
(A and B) Tumor DNAs were extracted from freshly microdissected tumors or paraffin-embedded pancreatic sections from mice 9 wk after mice were
infected with RCASBP-Bcl-xL or RCASBP-ALPP. PCR was performed using RCASBP-specific primers or ACTB (b-actin)–specific primers. The presence of
RCASBP proviruses in the genomic DNA was detected in ten of 25 tumors from mice infected with RCASBP-Bcl-xL (A) and two of the 20 tumors from
mice infected with RCASBP-ALPP (B).
(C) The presence of RCASBP proviruses in the genomic DNA was detected in nine of nine pancreatic lymph node metastases from mice infected with
RCASBP-Bcl-xL (n ¼ 4) or RCASBP-dnE-cad (n ¼ 5).
þ, RCASBP plasmid DNA used as template DNA in PCR; Normal, normal lymph node.
doi:10.1371/journal.pbio.0050276.g006
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with RCASBP-Bcl-xL, suggesting that overexpression of Bcl-xL
down-regulates cadherin 1. We also observed moderately
increased amounts of snail homolog 1 protein (Figure 8E), a
transcriptional repressor of cadherin 1 [29,30]. We also
performed immunoprecipitation (IP) experiments using two
anti–cadherin 1 antibodies (clones ECCD-2 and 36) and whole
cell extracts prepared from the uninfected tumor cells or
from the tumor cells infected with RCASBP-dnE-cad or
RCASBP-Bcl-xL. The immuoprecipitates were subjected to
Western blotting using the clone 36 antibody, which was
raised against the cytoplasmic domain of human cadherin 1
and cross-reacts with the mouse homolog. ECCD-2 was raised
against a mouse liver cadherin 1 fragment [31], and it did not
recognize dnE-cad (Figure 8F, lane 4). The levels of
endogenous cadherin 1 were not affected by overexpression
of dnE-cad in the tumor cells infected with RCASBP-dnE-cad
(Figure 8F, lane 1). In marked contrast, cadherin 1 was
considerably reduced in the tumor cells infected with
RCASBP-Bcl-xL (Figure 8F, lanes 3, 6, and 10).
To determine whether regulation of cadherin 1 levels was a
result of lowered mRNA levels, we surveyed tumor cell RNAs
with oligonucleotide arrays (Affymetrix). We observed that
the levels of cadherin 1 RNA were 36-fold lower in RIP-Tag;
RIP-tva tumor cells infected with RCASBP-Bcl-xL than in
uninfected parental cells (data not shown), suggesting that
Bcl-xL is likely to lower expression of cadherin 1 at the
transcriptional level. Surprisingly, we did not detect a
signiﬁcant reduction of cadherin 1 on the tumor cells
infected with RCASBP-Bcl-xL by immunostaining assays, using
the two anti–cadherin 1 antibodies (data not shown), raising
questions about the speciﬁcity of the antibodies used in the
assays. Taken together, overexpression of Bcl-xL reduces the
levels of cadherin 1 RNA and protein, and loss of cadherin 1
is likely to contribute to cell migration and invasion.
However, suppression of cadherin 1 function by dnE-cad is
not as efﬁcient as Bcl-xL in promoting invasion of b-cell
tumor cells (Figure 8B).
Bcl-xL Interacts with Myosins
The assembly and organization of the actin cytoskeleton
can be regulated by small guanosine triphosphatases
(GTPases) [32]. We evaluated whether the activities of four
members of the small GTPase family (RHO, CDC42, RAC1,
and RAS) were changed in the tumor cells infected with
RCASBP-Bcl-xL, by measuring the signaling activities of these
four small GTPases as reﬂected in the binding of GTP. Their
Figure 7. Redistribution of the Actin Cytoskeleton in RCASBP-Bcl-xL-Infected Tumor Cells
(A) Frozen pancreatic sections from a wild-type mouse (left panel), a mouse 2 wk after RCASBP-Bcl-xL infection (middle panel), and a mouse 5 wk after
RCASBP-ALPP infection (right panel) were stained with rhodamine-phalloidin for F-actin (red) and DAPI (blue). The presence of RCASBP-Bcl-xL proviral
DNA in the tumor (middle panel) was confirmed by PCR. Three mice each at 2 and 5 wk after RCASBP-Bcl-xL delivery and at 5 wk after RCASBP-ALPP
delivery were analyzed. Ex, exocrine tissue; I, islet; Tu, tumor tissue.
(B and C) RIP-Tag; RIP-tva tumor cells change morphology in vitro after being infected with RCASBP-Bcl-xL. (B) Bright-field images of uninfected tumor
cells and cells infected with RCASBP-GFP, RCASBP-Bcl-xL, or RCASBP-dnE-cad. Tumor cells infected with RCASBP-Bcl-xL have a less organized epithelial
sheet structure. Original magnification, 2003. (C) Tumor cells were cultured on chamber slides and immunostained with rhodamine-phalloidin for F-
actin. Tumor cells infected with RCASBP-Bcl-xL have decreased cortical actin. Scale bars, 20 lm. The images are representative of more than ten fields in
each experiment.
doi:10.1371/journal.pbio.0050276.g007
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transferase (GST)–fusion proteins to pull down GTP-bound
GTPases, which were detected by Western blotting using
antibodies against speciﬁc GTPases. However, no signiﬁcant
changes in the signaling strength of RHO, CDC42, RAC1, or
RAS were detected in the tumor cells infected with RCASBP-
Bcl-xL, compared with the uninfected parental cells (data not
shown), indicating that altered activities of these four
proteins were not responsible for the remodeling of the
actin skeleton in the tumor cells infected with RCASBP-Bcl-
xL. We cannot exclude the possibilities that small GTPase
activities vary spatially within the cells or that other members
Figure 8. Bcl-xL Has Profound Effects on Cell Migration and Invasion, and Reduces Cadherin 1 In Vitro
(A and B) Cell migration and invasion. Uninfected tumor cells or tumor cells infected with RCASBP-GFP, RCASBP-Bcl-xL, or RCASBP-dnE-cad were plated
in the upper chambers of transwell plates (A) or of Matrigel invasion plates (B). Data are presented as the mean numbers of cells counted in the lower
chambers in five fields under 203 magnification after 72 h, and are representative of three independent experiments.
(C and D) Proliferative and apoptotic indices of the four different cell lines. Cultures grown on chamber slides from uninfected tumor cells or cells
infected with RCASBP-GFP, RCASBP-Bcl-xL, or RCASBP-dnE-cad were stained with antisera against Ki67 (C) or activated caspase 3 (D). Data shown are the
mean percentage 6 standard deviation from triplicate experiments.
(E) Reduced protein levels of cadherin 1 and elevated snail homolog 1 levels in the tumor cell lines infected with RCASBP-Bcl-xL. Whole cell extracts
(WCE; 20 lg) from uninfected tumor cells or tumor cells infected with RCASBP-Bcl-xL were analyzed by Western blotting using antisera against the
cytosolic domain of cadherin 1 (clone 36), snail homolog 1, and Bcl-xL. Actin was measured as a loading control.
(F) Two anti–cadherin 1 antibodies (clones ECCD-2 and 36) were used to perform IP from whole cell extracts of uninfected tumor cells and tumor cells
infected with RCASBP-dnE-cad or RCASBP-Bcl-xL. The precipitates were subjected to Western blotting using an antibody against the cytosolic domain of
cadherin 1 (clone 36). Two lanes without WCE were used to identify the bands attributable to IgGs (lanes 7 and 11). A portion of nitrocellulose
membrane stained with Ponceau S is shown as a loading control.
doi:10.1371/journal.pbio.0050276.g008
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actin cytoskeleton when Bcl-xL is overexpressed.
To further investigate the mechanism by which Bcl-xL
increases cell motility, we sought to identify Bcl-xL-interact-
ing proteins by mass spectrometry. Bcl-xL is located both in
the cytosol and in mitochondrial membranes [33,34], whereas
BCL2, a related anti-apoptotic protein, is exclusively mem-
brane-bound [35]. We postulated that the cytosolic fraction of
Bcl-xL might contribute to its effects on cell shape, motility,
and invasiveness, so we prepared whole cell extracts from
tumor cells infected with RCASBP-Bcl-xL in two buffer
conditions, and used an anti-Bcl-xL antibody to co-precip-
itate interacting proteins. The antibody-bound complexes
were eluted from beads by boiling, separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), and visualized by silver staining. Although many
protein bands were present in the IP, we observed that the
intensities of several protein bands, including Bcl-xL itself,
were enhanced with increasing amounts of an anti-Bcl-xL
antibody (Figure 9A). These putative Bcl-xL-interacting
bands were excised and subjected to tryptic digestion, and
peptides were analyzed by mass spectrometry. The identities
of the proteins were BAX, myosin Va, and myosin, heavy
polypeptide 9, non-muscle isoform 1.
The current view of apoptotic regulation is that Bcl-xL and
its relatives bind to and thereby inhibit the pro-apoptotic
activity of BAX and BAK1, which are otherwise poised to
initiate the apoptotic cell death cascade [36,37]. Activated
BH3 sensors, such as BAD, bind to Bcl-xL-related proteins,
relieving suppression of BAX and BAK1. We conﬁrmed the
interaction between BAX and Bcl-xL in the b-cell tumor
cells infected with RCASBP-Bcl-xL by IP-Western blotting
(Figure 9B). We also observed an interaction between Bcl-xL
and BAD, but not phosphorylated BAD (Figure 9B). The
signiﬁcance of the reduction of phosphorylated BAD in the
tumor cells infected with RCASBP-Bcl-xL remains to be
determined.
We obtained an antibody against myosin Va and conﬁrmed
the presence of myosin Va in the anti-Bcl-xL IP (Figure 9B),
suggesting that the interaction between Bcl-xL and myosin Va
was speciﬁc and signiﬁcant. No suitable antibodies against the
other implicated myosin were found, so Western blotting to
verify its speciﬁcity by IP from the cells infected with
RCASBP-Bcl-xL was not possible. Furthermore, the associa-
tion between Bcl-xL and myosin Va was unlikely to be
mediated by the actin cytoskeleton, because actin was not
present in Bcl-xL IP (Figure 9B). Myosins have been
implicated in cell movement and migration [38–40], and
therefore it is possible that Bcl-xL promotes cell motility
through its interaction with myosins.
Discussion
The studies presented here demonstrate a system to
transfer cDNAs into premalignant lesions in mice to analyze
their effects on tumor progression. This system utilizes
RCASBP avian retroviral vectors to deliver cDNAs into
pancreatic b cells in RIP-Tag; RIP-tva bitransgenic mice
during tumorigenesis. This approach has the advantage of
introducing somatic genetic changes in a tissue-speciﬁc and
time-controlled fashion, which more faithfully mimics spora-
dic tumor development. It also avoids any potential pertur-
bation of normal tissue formation due to the ectopic
Figure 9. Bcl-xL Interacts with BAX, Unphosphorylated BAD, and Myosin Va in the Tumor Cells Infected with RCASBP-Bcl-xL
(A) Whole cell extracts of tumor cells infected with RCASBP-Bcl-xL were prepared in cell lysis buffer containing 150 mM NaCl or 100 mM (NH4)2SO4 (L100
buffer), and subjected to IP with increasing amounts of an anti-Bcl-xL antibody. The precipitates and 5 ng of recombinant human Bcl-xL (rBcl-xL) were
analyzed by SDS-PAGE and silver staining. The putative Bcl-xL-interacting bands (open arrowheads) were excised from the gel for mass spectrometry.
The identities of the proteins are listed. Both myosin Va and myosin, heavy polypeptide 9, non-muscle isoform 1 were identified by mass spectrometry
using proteins from the excised area labeled ‘‘(1).’’
(B) Whole cell extracts of uninfected tumor cells and tumor cells infected with RCASBP-Bcl-xL were prepared in L100 buffer, and subjected to IP with an
anti-Bcl-xL antibody. The precipitates were analyzed by SDS-PAGE and Western blotting using specific antibodies against Bcl-xL, BAX, BAD, phospho-
BAD, myosin Va, and actin. Four of these proteins, Bcl-xL, BAX, BAD, and myosin Va, were found in anti-Bcl-xL IP from cells infected with RCASBP-Bcl-xL.
doi:10.1371/journal.pbio.0050276.g009
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much faster to generate vectors carrying genes of interest
than to generate transgenic mice. In addition, using cell lines
derived from b-cell tumors in RIP-Tag; RIP-tva bitransgenic
mice, further biochemical and phenotypic analysis can be
performed, taking advantage of the high efﬁciency of viral
infection in vitro.
The low efﬁciency of in vivo infection has been a limitation
of using the RCAS-TVA system [13,14]. Here, we were able to
achieve 10%–20% in vivo infection efﬁciency in hyperplastic
pancreatic islet b-cell lesions using high viral titer (.10
8
infectious units per milliliter) and the intra-cardiac route to
deliver the RCASBP viruses into mice. Since not all the
premalignant lesions are infected with the RCASBP vectors
and 2%–4% of islets develop into tumors in the RIP-Tag; RIP-
tva bitransgenic mice without viral infection, only the factors
that confer a selective advantage over the natural course of
tumorigenesis in RIP-Tag; RIP-tva mice can be identiﬁed.
Moreover, the percentage of RCASBP-Bcl-xL-positive tumors
decreases over time as the uninfected RIP-Tag; RIP-tva cells
gradually develop into tumors. In particular, RCASBP vectors
carrying genes that promote metastasis will be most easily
recognized, because metastasis to pancreatic lymph nodes or
other organs does not normally occur in RIP-Tag; RIP-tva
mice. Although tumors are likely to be clonally expanded
from single cells infected with RCASBP vectors carrying
progression factors, we were not able to show whether the
tumors were clonal because of the limited DNA materials
isolated from the small tumors in this study.
We delivered RCASBP viruses carrying tumor progression
factors into RIP-Tag; RIP-tva bitransgenic animals at 7 wk of
age, when hyperplastic islets develop. Analogous to the results
obtained from RIP1-Tag2; RIP1-dnE-cad bitransgenic mice
[22], we demonstrated that introduction of RCASBP-dnE-cad
into the hyperplastic islets of RIP-Tag; RIP-tva animals
promoted invasive tumor formation and metastases to the
pancreatic lymph nodes. Mice at other ages could also be used
to study whether the time at which the candidate factors are
introduced inﬂuences the outcome, as long as islet cells
undergo cell division to allow infection. For example, the
transforming growth factor b1 (TGFB1) receptor can act as a
tumor suppressor at early stages of tumor development, but
at later stages TGFB1 responsiveness promotes invasion and
metastasis [41,42]. Moreover, a combination of several
RCASBP viruses encoding different factors of interest could
be used for infection simultaneously or sequentially, and the
proviral DNA could be isolated from especially metastatic
malignant tumors to identify single factors or combinations
of factors that may contribute to the malignancy. However,
this approach is limited by the inability of the RCASBP vector
to accommodate cDNAs greater than 2.5 kb in size.
The effects of overproducing Bcl-xL via somatic gene
transfer were provocative and unexpected. First, no signiﬁ-
cant protection against apoptosis was found either in the
tumors from mice infected with RCASBP-Bcl-xL or in the
tumor cells infected with RCASBP-Bcl-xL in vitro. These
ﬁndings are quite distinct from the demonstrable anti-
apoptotic effect seen when Bcl-xL was expressed via a
transgene in all islet b cells throughout tumorigenic ontogeny
in the RIP1-Tag2 model [25], as well as in MYC transgenic
mice [26]. It remains possible that Bcl-xL contributes to cell
survival at earlier stages (hyperplasia/angiogenesis) or a later
stage (metastasis) in mice infected with RCASBP-Bcl-xL.
Additionally, we cannot exclude episodic effects on apoptosis
when tumors were forming, as opposed to chronic effects
detectable at the later time points of our analysis. This
apparent insensitivity of b-cell tumors to the anti-apoptotic
effect of Bcl-xL deserves future investigation. Notably, a
similar phenotype of increased invasiveness without suppres-
sion of apoptosis has been observed when another apoptotic
modulator was overexpressed in the RIP1-Tag2 mice. Exog-
enous production of IGF1R for the IGF1/2 survival factors in
all islet b cells caused increased invasiveness and lymph node
metastasis, with increased (not decreased) apoptosis in the
premalignant stages, while having no impact on the tumor
stages [23]. Yet elimination of the gene encoding IGF2
produced highly apoptotic tumors with reduced growth,
demonstrating the importance of anti-apoptotic signaling for
islet tumorigenesis [43]. The similar consequences of ectopi-
cally expressing Bcl-xL and IGF1R may imply mechanistic
similarity that should be further explored.
Second, we observed that the actin cytoskeleton was
rearranged in invasive tumors infected with RCASBP-Bcl-xL,
presumably contributing to increased motility. In addition,
tumor cells infected with RCASBP-Bcl-xL in vitro displayed
altered morphology, abnormal cortical distribution of the
actin cytoskeleton, and elongated cell shape. The morpho-
logical changes in tumor cells infected with RCASBP-Bcl-xL
may contribute to enhanced cell migration and invasion as
observed in the two-chamber assays.
Third, as measured by Western blotting and cDNA micro-
array expression proﬁling, the epithelial cell–cell junction
protein, cadherin 1, was down-regulated and a transcriptional
repressor of cadherin 1, snail homolog 1, was up-regulated in
the tumor cells infected with RCASBP-Bcl-xL. These changes
may contribute to the rearrangement of the actin cytoskele-
ton and diminish the strength of cellular adhesion. Indeed,
tumor cells infected with RCASBP-Bcl-xL exhibited a strong
capability to migrate through transwell membrane and to
invade through Matrigel, but the mechanism by which Bcl-xL
regulates cadherin 1 remains to be determined.
Finally, the identiﬁcation of a novel Bcl-xL-interacting
protein, myosin Va, may help to explain the pro-invasive
activity of Bcl-xL. Myosins belong to a superfamily of actin-
based motor proteins comprising at least 15 classes [39].
There are two main groups of myosins: the conventional,
well-characterized myosin II class of muscle and non-muscle
cells and the unconventional myosins. The myosin II class is
referred to as ‘‘conventional myosin’’ because for many years
this was the only class of myosin known; members of this class
are able to form ﬁlaments and are involved in muscle
contraction, cell migration, and cytokinesis. The functions
of most of the unconventional myosins are not known, but
some have been shown to participate in the extension of
processes at the leading edge of crawling cells. For example,
myosin I is required for formation of pseudopod extensions
in the amoeba Dictyostelium, and myosin V for extension of
ﬁlopodia in neurons [44,45].
By comparing the effects of suppressing the function of
cadherin 1 with dnE-cad and overproducing Bcl-xL, we have
highlighted the provocative pro-invasive activity of Bcl-xL.
Cadherin 1 is a well-established barrier to invasive growth in
many other epithelial cancers [46], and its suppression
enables invasive growth of pancreatic b-cell tumors in
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invasive phenotype in a Matrigel invasion assay of cultured
tumor cells than did dnE-cad, supporting the proposition
that Bcl-xL has roles other than suppression of cadherin 1
that enhance the invasive growth phenotype. The levels of
endogenous cadherin 1 in these two types of cells could
contribute to the differences. Whereas endogenous cadherin
1 protein levels were not affected when the dominant-
negative form was introduced into the cells, cadherin 1 was
down-regulated in the tumor cells infected with RCASBP-Bcl-
xL. This effect could reduce cell–cell adhesion and also affect
the organization of the actin cytoskeleton. On the other hand,
the frequency of lymph node metastasis was similar in RIP-
Tag; RIP-tva mice infected with RCASBP-Bcl-xL and RCASBP-
dnE-cad. It is possible that the b-cell tumor microenvironment
in vivo is less discriminating than Matrigel, a solubulized
basement membrane preparation extracted from a mouse
sarcoma [47].
The BCL2 family proteins function in carcinogenesis by
preventing apoptosis of tumor cells, instead of promoting cell
proliferation [48]. Of the BCL2 family members, BCL2 and
Bcl-xL are most closely related to each other, and repress cell
death through common mechanisms [49,50]. However, several
lines of evidence indicate that they are not functionally
equivalent in tumorigenesis. In primary breast cancer, over-
expression of Bcl-xL is associated with higher tumor grade
and nodal metastasis, and overexpression of Bcl2 is correlated
with lower tumor grade and smaller tumor size [51]. More-
over, nude mice with orthotopic implants of human breast
cancer cells transfected with Bcl-xL, but not BCL2, develop
lymph node metastasis [52]. Our ﬁndings suggest that Bcl-xL
enhances cell motility, remodels the actin cytoskeleton,
down-regulates cadherin 1, and interacts with myosin Va
without affecting cell proliferation or apoptosis. It remains to
be investigated whether these properties are unique to Bcl-xL
among the BCL2 family members.
In conclusion, we have developed a mouse model to assess
the effect of candidate genes in tumor progression, without
the need to generate conditional transgenic lines in which
genes of interest are expressed at different stages of tumori-
genesis. Thus far, we have employed this approach to improve
our knowledge of the contribution of Bcl-xL to tumor
invasion and metastasis. We postulate that Bcl-xL has a pro-
invasive function other than its anti-apoptotic activity. Given
that many somatic gene mutations and altered expression of
thousands of genes have been discovered in cancers, it will
not be a simple task to verify that each candidate gene is
important during carcinogenesis. By delivering libraries of
retroviruses encoding candidate factors or inhibitory RNAs
into transgenic mice, it may be possible to screen many of the
genes for effects during tumorigenesis in a variety of tissues.
Materials and Methods
Mouse strains. The elastase-tva transgene construct [53] was
digested with BamHI and HindIII to release a 800-bp tva cDNA
fragment encoding the glycosylphosphatidylinisotol-anchored form
of the receptor. This cDNA fragment was cloned into a BglII- and
HindIII-digested pSG5 vector with an expanded multiple cloning
site (gift of E. Emison, Johns Hopkins University). The tva cDNA
was then released by XbaI/HindIII digestion of the pSG5-tva
plasmid and subcloned into a XbaI/HindIII-digested RIP-DIPA
plasmid that contains the RIP 59 to the XbaI site and the SV40
small t intron and terminator sequences 39 to the HindIII site.
The resulting RIP-tva transgene construct was released from the
pBR322 vector backbone by digestion with BamHI, puriﬁed, and
resuspended in TE for pronuclear injection. RIP-tva transgenic
founders on a CBA/CAJ 3 C57BL/6 mixed genetic background
were backcrossed for ten generations onto a pure C57BL/6 back-
ground. The RIP-tva mice were crossed with the previously
described RIP1-Tag2 mice [11] to obtain RIP-Tag; RIP-tva mice.
All mice were housed in accordance with institutional guidelines.
Genotypes were determined by PCR using tail DNA. PCR primers
for TVA were 59-GCCCTGGGGAAGGTCCTGCCC-39 and 59-
CTGCTGCCCGGTAACGTGACCGG-39.
b-cell tumor cell line. A pancreatic b-cell tumor cell line (bTC-
N134) was derived from a tumor from a RIP-Tag; RIP-tva bitransgenic
animal at 16 wk of age, and maintained in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
0.2 mM L-glutamine, and 1% penicillin/streptomycin in a humidiﬁed
37 8C incubator under 5% CO2; method modiﬁed from [54].
Viral propagation and delivery. RCASBP is a replication-compe-
tent avian leukosis virus with a splice acceptor and the Bryan-RSV pol
gene. RCASBP-ALPP has been described previously [55]. RCASBP-
GFP was a gift from Maureen Peters and Constance Cepko, Harvard
Medical School. Human Bcl-xL cDNA was a gift from Stanley
Korsmeyer, Dana-Farber Cancer Institute. RCASBP-dnE-cad (myc-
tagged, mouse origin) and RCASBP-Bcl-xL were generated by Yi Li
and William Pao, respectively, in the Varmus laboratory. The
production of the dnE-cad and Bcl-xL was veriﬁed by Western blot
analysis. Chicken ﬁbroblasts DF-1 [56,57] transfected with RCASBP
vectors were maintained in DMEM supplemented with 10% FBS, 0.2
mM L-glutamine, and 1% penicillin/streptomycin in a humidiﬁed 37
8C incubator under 5% CO2. For in vitro infection, RCASBP viral
supernatant was passed through a 0.45-lm ﬁlter to obtain cell-free
viruses and used as growth medium for the RIP-Tag; RIP-tva
pancreatic b-cell tumor cell line once a day for 2–3 d. For in vivo
infection, viral supernatant was passed through 0.45-lm ﬁlters and
was concentrated by high-speed ultracentrifugation at 23,000 rpm for
1.5 h before intra-cardiac injection into mice. Intra-cardiac injection
was performed as described [58]. Viral titer was determined by end-
point dilution of DF-1 producer cells. PCR primers for RCASBP were
59-ACCGGGGGATGCGTAGGCTTCA-39 and 59-CCGCAACACC-
CACTGGCATTACC-39.
Tissue preparation. Tissues were removed and either ﬁxed in 10%
buffered formalin overnight at room temperature or immediately
placed in OCT and frozen on dry ice. Fixed and frozen tissues were
processed and cut into 5-lm and 10-lm sections, respectively, at
Histoserv (http://www.histoservinc.com/index.php).
Immunohistochemical analysis. Formalin-ﬁxed/parafﬁn-embedded
sections were deparafﬁnized and rehydrated by passage through a
graded xylene/ethanol series before staining. Cells were cultured on
glass chamber slides for 3 d before ﬁxation in 4% paraformaldehyde
in PBS for 20 min, and were permeabilized by 0.1% Triton X-100 (in
PBS) for 4 min. Immunochemistry with VECTASTAIN Elite ABC Kit
(Vector Laboratories, http://www.vectorlabs.com/) was performed
according to the manufacturer’s instructions. Primary antibodies
used were mouse anti–SV40 T antigen (1:400; Calbiochem, http://
www.emdbiosciences.com/html/CBC/home.html), rabbit anti-insulin
(1:600; Immunostar, http://www.immunostar.com/), rabbit anti-synap-
tophysin (1:100; Dako, http://www.dako.com/), rabbit anti-Ki67
(1:1,000; Novocastra, Vision BioSystems, http://www.leica-
microsystems.com/biosystems.html), and rabbit anti–activated cas-
pase 3 (1:100; Cell Signaling Technology, http://www.cellsignal.com/).
Immunoﬂuorescent analysis. Frozen sections were air-dried over-
night at room temperature and ﬁxed in cold acetone for 10 min.
Formalin-ﬁxed/parafﬁn-embedded sections were deparafﬁnized and
rehydrated by passage through a graded xylene/ethanol series. Cells
were cultured on glass chamber slides for 3 d before ﬁxation in 4%
paraformaldehyde in PBS for 20 min, and permeabilized by 0.1%
Triton X-100 (in PBS) for 4 min. After blocking, slides were incubated
with primary antibodies overnight at 4 8C or for 1 h at room
temperature. After three washes of TBS-T, slides were incubated with
secondary antibodies for 1 h at room temperature. Primary anti-
bodies used were rabbit anti-TVA (1:200; gift of Andrew Leavitt,
University of California San Francisco), goat anti-mouse PDX1
(1:2,000; gift of Chris Wright, Vanderbilt University), and rhod-
amine-phalloidin (1:40; Invitrogen, http://www.invitrogen.com/).
TRITC-donkey anti-rabbit IgG (1:200) and FITC-donkey anti-goat
IgG (1:200) were purchased from Jackson ImmunoResearch Labo-
ratories (http://www.jacksonimmuno.com/). To stain DNA, slides were
incubated with DAPI (49,6-diamidino-2-phenylindole; 5 lg/ml in PBS)
for 15 min at room temperature.
FACS. Pancreases were perfused and digested into small pieces
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Mouse Model for Assessing Tumor Progressionwith collagenase (Sigma-Aldrich, http://www.sigmaaldrich.com/) at 37
8C for 15 min, and were centrifuged in a Ficoll gradient (11%, 20.5%,
23%, and 25% [w/v]) as described [19]. Partially digested pancreatic
tissues in the top two layers of the gradient were further digested and
dispersed into single-cell suspension as described [20]. After blocking
with 3% donkey serum at 4 8C for 30 min, cells were incubated with
rabbit anti-TVA antibodies at 4 8C for 30 min, incubated with donkey
Cy5-conjugated anti-rabbit antibodies at 4 8C for 30 min, and
analyzed for Cy5 and GFP by FACS using a BD Biosciences (http://
www.bdbiosciences.com/) FACS-DiVa Cell Sorter or FACSCalibur
ﬂow cytometer.
Western blot analysis. To prepare whole cell extracts, cells were
lysed in buffer containing 100 mM NaCl, 100 mM Tris (pH 8.2), 0.5%
NP-40, and protein inhibitor cocktail at 4 8C. Then 20 lg of total
proteins were separated by SDS-PAGE and electrotransferred onto
nitrocellulose membranes. The membranes were stained with
Ponceau S and immunoblotted with rabbit anti-Bcl-xL antibody
(1:1,000; Cell Signaling Technology), mouse anti–cadherin 1 antibody
(clone 36, 1:1,000; BD Biosciences), rabbit anti-actin antibody
(1:5,000; Sigma-Aldrich), rabbit anti–snail homolog 1 (1: 1,000;
Abcam, http://www.abcam.com/), rabbit anti-BAX antibody (1:1,000;
Cell Signaling Technology), rabbit anti-BAD antibody (1:1,000; Cell
Signaling Technology), mouse anti-phospho-BAD (Ser112) antibody
(1:1,000; Cell Signaling Technology), rabbit anti–myosin Va antibody
(1:1,000; Sigma-Aldrich), and appropriate secondary antibodies. The
proteins were detected with ECL chemiluminescent substrate (GE
Healthcare, http://www.gehealthcare.com/) on Kodak (http://www.
kodak.com/) BioMax MR ﬁlms.
In vitro migration and invasion assays. Transwell chambers with 8-
lm porous polycarbonate membranes (Corning, http://www.corning.
com/) and invasion chambers with 8-lm porous polyester membranes
and coated with Matrigel basement membrane matrix (BD Bioscien-
ces) were used. One million cells were plated in the upper chambers
in DMEM containing 2% FBS, 0.2 mM L-glutamine, and 1%
penicillin/streptomycin. The lower chambers were ﬁlled with DMEM
containing 10% FBS, 0.2 mM L-glutamine, and 1% penicillin/
streptomycin. After a 72-h incubation in a humidiﬁed 37 8C
incubator under 5% CO2, cells migrating or invading into the
bottom chambers were ﬁxed, stained with hematoxylin, and counted
in ﬁve ﬁelds under 2003 magniﬁcation.
IP. To prepare whole cell extracts for anti-Bcl-xL IP, cells were
lysed in cell lysis buffer containing 150 mM NaCl according to the
manufacturer’s instructions from Cell Signaling Technology or in
L100 buffer [59] containing protein inhibitor cocktail at 48C for 30
min. The extracts were precleared with protein A Sepharose beads
for 1 h at 4 8C. Rabbit anti-Bcl-xL antibody (Cell Signaling
Technology) was mixed with the extracts for at least 4 h at 4 8C,
and then protein A Sepharose beads were added for 1 h at 4 8C. The
precipitates were washed extensively and were eluted from the beads
by boiling in Laemmli buffer. Recombinant human Bcl-xL and BCL2
proteins were purchased from R&D Systems (http://www.rndsystems.
com/). Anti–cadherin 1 IP using two anti–cadherin 1 antibodies—
clone ECCD-2 (Zymed, http://www.invitrogen.com) and clone 36 (BD
Biosciences)—was performed as described [60] except that protein A/
G plus-agarose (Santa Cruz Biotechnology, http://www.scbt.com/) was
used instead of protein A Sepharose beads.
Supporting Information
Accession Numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez?db¼gene)
accession numbers for gene products discussed in this paper are BAD
(12015), BAX (12028), cadherin 1 (12550), myosin Va (17918), myosin,
heavy polypeptide 9, non-muscle isoform 1 (17886), PDX1 (18609),
snail homolog 1 (20613), and TVA (420066).
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